Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 Pipeline Review, H2 2017 [Report Updated: 07112017] Prices from USD $3500
Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 Pipeline Review, H2 2017
Summary
Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 4 Pipeline Review, H2 2017, outlays comprehensive information on the Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 Cyclindependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thrkinase component of cyclin DCDK4 DC complexes phosphorylate and inhibit members of the retinoblastoma RB protein family including RB1 and regulate the cellcycle during G1/S transition. Activation of the cyclinDCDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex. The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 3, 1, 1, 12 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Genito Urinary System And Sex Hormones and Toxicology which include indications Breast Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Lymphoma, NonSmall Cell Lung Cancer, Colon Cancer, Colorectal Cancer, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Liposarcoma, Metastatic Hepatocellular Carcinoma HCC, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Melanoma, Oligodendroglioma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme GBM, Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Acute Renal Failure ARF Acute Kidney Injury, Anaplastic Oligoastrocytoma, Astrocytoma, Bacterial Infections, Brain Tumor, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large BCell Lymphoma, Duodenal Cancer, Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, EpsteinBarr Virus HHV4 Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme GBM, Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Leukemias, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Metastatic Transitional Urothelial Tract Cancer, Multiple Myeloma Kahler Disease, Myelosuppression, Neuroblastoma, Neuroendocrine Tumors, Peritoneal Cancer, Primary CNS Lymphoma, Prostate Cancer, Rheumatoid Arthritis, SmallCell Lung Cancer and Squamous NonSmall Cell Lung Cancer.
Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22
The report reviews Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics and enlists all their major and minor projects
The report assesses Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
